Standard Craniectomy Against Laparotomy for the Treatment of Traumatic Rise in Intracranial Pressure and the Effect on Long-term Outcome (SCALPEL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05115929|
Recruitment Status : Recruiting
First Posted : November 10, 2021
Last Update Posted : May 16, 2023
|First Submitted Date ICMJE||October 10, 2021|
|First Posted Date ICMJE||November 10, 2021|
|Last Update Posted Date||May 16, 2023|
|Actual Study Start Date ICMJE||October 1, 2022|
|Estimated Primary Completion Date||December 2025 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Functional outcome measured by the extended Glasgow Outcome Scale (GOS-E) [ Time Frame: 12 months post-injury ]
8 Good recovery Upper no current problems related to the brain injury that affect daily life; 7 Good recovery Lower minor problems that affect daily life; resumes >50% of the pre-injury level of social and leisure activities; 6 Moderate disability Upper reduced work capacity; resumes <50% of the pre-injury level of social and leisure activities; 5 Moderate disability Lower unable to work or only in sheltered workshop; 4 Sever disability Upper can be left alone > 8h during the day, but unable to travel and/or go shopping without assistance; 3 Sever disability Lower requires frequent help of someone to be around at home most of the time every day; 2 Persistent vegetative state unresponsive and speechless; 1 Death [higher scores mean better outcomes]
|Original Primary Outcome Measures ICMJE||Same as current|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||Standard Craniectomy Against Laparotomy for the Treatment of Traumatic Rise in Intracranial Pressure and the Effect on Long-term Outcome|
|Official Title ICMJE||Standard Craniectomy Against Laparotomy for the Treatment of Traumatic Rise in Intracranial Pressure and the Effect on Long-term Outcome|
|Brief Summary||Intractable high intracranial pressures (ICP) are associated with poor functional outcomes and mortality, so the SCALPEL trials aims to evaluate the effect of decompressive craniectomy against decompressive laparotomy to lower those pressures in diffuse TBI. The primary outcome measure for that evaluation is functional outcome after 12 months on the extended Glasgow Outcome Scale (GOS-E).|
Rationale for trial:
Traumatic brain injuries (TBI) are held responsible for about half of the trauma related death rate and a main driver of trauma related morbidity. While outcomes from trauma have improved in the last decades, the mortality and morbidity caused by TBI stayed about the same.
The surgical interventions for raised ICP in TBI have been studied extensively with varying outcome. Craniectomy did reduce mortality in several trials. There were additional survivors with favorable neurological outcome, as well as additional survivors with poor functional outcome. That effect might partly be explained by the inherent morbidity of the craniectomy or the consecutive cranioplasty. Various studies have shown surgical complications post cranioplasty in around one third of the cases including reoperation for hematoma, hydrocephalus, seizures, and graft infections and there is evidence for negative effects due to the rapid decompression of the pressure as growing hematoma size.
Decompressive laparotomy (DL) on the other side is thought to lower not only the dynamic pulsatile effect on the brain, it also causes increased venous outflow from the brain which reduces the intracranially present amount of venous blood and therefore ICP.
It is hypothesized that a decompressive laparotomy may have the benefit of lowering the ICP, without the inherent risks and complications caused by a large craniectomy and its influence on long-term outcome.
This trial seeks to inform future guidelines about this potentially alternative intervention in TBI patients. Another potential benefit might be in the applicability of the findings in settings without neurosurgical capabilities (expertise or instruments) like in military conflicts, rural areas, or developing countries.
If the treating team involving a neurosurgeon and a general, abdominal, or trauma surgeon depending on the local setting and jurisdiction agree that the participant matches the eligibility criteria, consent is given and no exclusion criteria are met, the participant can be enrolled in the trial.
Enrolment of a participant:
If a potential participant is admitted to a study center the local principal investigator (PI) is informed. If the local team is uncertain about eligibility or exclusion, advice from a senior clinician of the trial management committee (TMC) will be provided.
If after all there is still uncertainty about the potential eligibility, the patient will not be enrolled in the trial.
By definition the included participants will be unable to give written consent to participation in this study. In those cases, the investigators plan to discuss the procedures and the trial with the next of kin and acquire consent for the participant.
There are cases imaginable when the next of kin is unknown, cannot be reached, or there is no time to arrive and have that detailed discussion, due to the emergence of that immediate life-threatening condition. Those situations are covered by the Declaration of Helsinki. Detailed standard operating procedures as discussed in the SCALPEL Study Protocol, will be put in place together with the participating centers and the ethical monitoring board.
The investigators plan to set up 10 international centers in order to increase external validity of the trial and to complete the inclusion phase within 3 years.
The medical and interventional therapies included in step I and II are representing the current standard of care and are discussed extensively in the guidelines for severe traumatic brain injuries.
Step I includes head elevation 30-45°, adequate sedation, neuroprotective ventilation, sufficient analgesia and the use of vasopressors if necessary to support cerebral perfusion pressure. Monitoring includes measurement of ICP, IAP, and mean airway pressure. Those measures are all considered to be mandatory before progressing to randomization.
Step II includes ventriculostomy and drainage of CSF, infusion of mannitol or hypertonic saline, as well as therapeutic hypothermia. Those measures are considered to be facultative. The latter two are not of proven value, or might even be harmful, so the local team can very well skip those measures with respect to the local centers guidelines.
If the ICP remains over 25 mmHg for 1-12h and the inclusion criteria are met, without any exclusion criteria the patient can be randomized in the surgical intervention groups.
If randomized to the craniectomy treatment arm, it is discretionary to the treating neurosurgeon if a bifrontal vs. frontotemporoparietal hemicraniectomy is performed, depending on the clinical situation and local protocols. The bone flap should be generous. Secondary to the decompression there will be the necessity for a cranioplasty after resolving of the brain swelling 2 to 20 weeks after craniectomy.
The performance of the decompressive craniectomy is described in the Appendix B of the SCALPEL Study Protocol - Best practice guideline for the decompressive craniectomy in the SCALPEL trial.
If randomized to the laparotomy treatment arm, A long median laparotomy will be performed in the laparotomy group. The skin and fascia is left open after that as a laparostomy. It is covered by a negative pressure dressing or other adequate laparostomy dressings according to the local protocols. A traction-free mesh should be used with the fascial edges.
To further improve the procedural safety and effectiveness the investigators plan to monitor the effect on ICP for one hour directly in the operating theater after the negative pressure dressing is applied and before the patient is transferred to the neurosurgical ICU. Neurocritical care measures like head elevation 30-45°, adequate sedation, neuroprotective ventilation, sufficient analgesia and the use of vasopressors if necessary to support cerebral perfusion pressure, will be performed during that period as it would be done on the ICU ward.
Secondary to the decompression the closure of the fascia and skin is needed. If the ICP and neurological recovery of the patient allows, it is encouraged to perform the closure around 7-14 days after decompression. In the case-control study out of the Shock Trauma Center survivors were allowed to granulate and then closed with Vicryl mesh and split thickness skin grafting, this option is not recommended anymore due to improved laparostomy management. The performance of the decompressive laparotomy and the management of the open abdomen is described in the Appendix A of the SCALPEL Study Protocol - Best practice guideline for the decompressive laparotomy in the SCALPEL trial.
Follow up assessments:
GOS-E and EQ-5D will be evaluated at follow-up at 6 and 12 months in keeping with the IMPACT group recommendations. The investigators will use postal questionnaires, pre-paid envelopes, phone call reminders, structured phone call interviews and face-to-face interviews if necessary. The protocol does not allow members of the acute care team to participate in those interviews.
The questionnaires will be collected centrally, and two examiners will determine the outcome scores independently from each other.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Not Applicable|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
|Condition ICMJE||Traumatic Brain Injuries|
|Study Arms ICMJE||
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Recruiting|
|Estimated Enrollment ICMJE
|Original Estimated Enrollment ICMJE||Same as current|
|Estimated Study Completion Date ICMJE||August 2026|
|Estimated Primary Completion Date||December 2025 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages ICMJE||18 Years to 65 Years (Adult, Older Adult)|
|Accepts Healthy Volunteers ICMJE||No|
|Listed Location Countries ICMJE||France, Germany|
|Removed Location Countries|
|NCT Number ICMJE||NCT05115929|
|Other Study ID Numbers ICMJE||2021_10_SK1|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||
|IPD Sharing Statement ICMJE||
|Current Responsible Party||Technical University of Munich|
|Original Responsible Party||Same as current|
|Current Study Sponsor ICMJE||Technical University of Munich|
|Original Study Sponsor ICMJE||Same as current|
|Investigators ICMJE||Not Provided|
|PRS Account||Technical University of Munich|
|Verification Date||May 2023|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP